Lisinopril Side Effects: Incidence Rates Across Clinical Trials

What the Largest Trials Tell Us About Lisinopril's Adverse Event Profile

The adverse-event data for lisinopril comes from several large randomized controlled trials, the FDA prescribing label, and the FDA Adverse Event Reporting System (FAERS). Each source captures a different slice of real-world risk. Trial data reflects controlled populations; FAERS captures spontaneous post-market reports where causality is less certain but signal detection is broader.

The FDA-approved lisinopril prescribing label lists adverse reactions observed in placebo-controlled clinical trials. In hypertension trials, the most frequent adverse events were hypotension (1.2%), dizziness (3.5%), headache (5.3%), diarrhea (3.7%), upper respiratory symptoms (2.2%), and fatigue (3.0%). In heart-failure trials, the profile shifted: hypotension rose to 8.1%, chest pain appeared at 3.4%, and syncope was reported in 1.5% of patients [1].

ALLHAT: The Benchmark for Comparative Safety

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT, N=33,357) compared lisinopril to chlorthalidone and amlodipine in high-risk hypertensive adults over a mean 4.9 years [2]. Lisinopril was associated with a significantly higher rate of angioedema compared to chlorthalidone (relative risk 3.88, 95% CI 1.65 to 9.13, P<0.001). Black participants randomized to lisinopril had a 40% higher rate of stroke versus chlorthalidone, partly attributed to less effective blood pressure reduction in this subgroup rather than a direct toxic effect [2].

GISSI-3: Post-MI Populations

In GISSI-3 (N=19,394), lisinopril 5 to 10 mg/day was started within 24 hours of acute MI [3]. Persistent hypotension occurred in 10.4% of lisinopril patients versus 8.0% in controls (P<0.001), and renal dysfunction occurred in 2.2% versus 1.1% in controls [3]. These numbers inform the caution required when initiating ACE inhibitors early after MI, particularly in patients with borderline perfusion.

ATLAS: Dose-Dependent Adverse Events

The Assessment of Treatment with Lisinopril and Survival (ATLAS) trial randomized 3,164 heart-failure patients to low-dose (2.5 to 5 mg) versus high-dose (32.5 to 35 mg) lisinopril [4]. Dizziness occurred in 19% (high-dose) versus 17% (low-dose). Hypotension occurred in 9% versus 7%. High-dose lisinopril produced a statistically significant reduction in the combined endpoint of all-cause mortality or hospitalization (relative risk 0.88, P<0.002) despite the modestly higher adverse-event burden [4]. That means clinicians face a genuine trade-off: more side effects at higher doses, but better cardiovascular outcomes.

Dry Cough: The Most Common Reason Patients Stop Lisinopril

Dry cough is the single most frequent cause of ACE inhibitor discontinuation. The mechanism is accumulation of bradykinin and substance P in the respiratory tract following ACE inhibition [5].

Incidence Across Populations

Published incidence ranges widely by race and study design. A meta-analysis of 125 trials (N=198,130) published in the Journal of the American Medical Association found an overall ACE inhibitor cough rate of approximately 11.5% [6]. In patients of East Asian descent, rates reach 30 to 39% [7]. In predominantly White European cohorts, rates hover around 5 to 10%.

The FDA prescribing label reports cough at 3.5% in controlled hypertension trials, but those trials were not powered to stratify by race and likely underrepresent susceptible populations [1].

Clinical Management

Cough typically appears within the first 1 to 3 weeks and resolves within 1 to 4 weeks of discontinuation. Switching to an angiotensin receptor blocker (ARB) such as losartan or valsartan eliminates the cough mechanism entirely. A Cochrane review of 13 trials confirmed that ARBs produce cough at rates statistically indistinguishable from placebo [8].

Angioedema: Rare but Potentially Fatal

Angioedema from lisinopril involves bradykinin-mediated swelling of the face, lips, tongue, larynx, and sometimes the intestinal wall. The laryngeal form can be fatal without prompt airway management.

Overall Incidence Rates

The FDA label reports angioedema in 0.1% of patients in controlled trials [1]. Post-market surveillance and registry data suggest real-world rates of 0.1 to 0.5% [9]. ALLHAT found a 3-fold to 4-fold higher risk in Black patients versus White patients [2]. A study using the UK Clinical Practice Research Datalink (N=248,720 ACE inhibitor users) found an angioedema incidence of 0.45 per 1,000 patient-years, with the highest risk in the first month of therapy [9].

Risk Factors and Timing

Risk factors for ACE inhibitor angioedema include Black race, prior angioedema of any cause, use of mTOR inhibitors (e.g., everolimus), dipeptidyl peptidase-4 (DPP-4) inhibitors, and tissue plasminogen activator (tPA) co-administration [10]. Roughly 50 to 65% of ACE inhibitor angioedema cases occur in the first month; a smaller number emerge after years of uneventful use [9].

The American College of Allergy, Asthma, and Immunology guideline states: "ACE inhibitor-induced angioedema is a class effect and patients who experience it should not be rechallenged with any ACE inhibitor" [10].

Hyperkalemia: A Dose- and Comorbidity-Dependent Risk

ACE inhibitors reduce aldosterone secretion, which impairs urinary potassium excretion. Clinically significant hyperkalemia (K+ >5.5 mEq/L) is uncommon in patients with normal renal function but rises sharply in CKD, diabetes, and heart failure.

Trial-Based Incidence

In ATLAS, hyperkalemia requiring dose reduction or discontinuation occurred in approximately 6% of the high-dose group versus 3% of the low-dose group [4]. A large observational study published in BMJ (N=1,227,065 new ACE inhibitor users) found a 30-day hyperkalemia hospitalization rate of 0.04% in low-risk patients rising to 0.16% in those with CKD stage 3b or worse [11].

Monitoring Protocol

The 2022 ACC/AHA Guideline for Heart Failure recommends checking serum potassium and creatinine within 1 to 2 weeks of initiating an ACE inhibitor and after any dose increase [12]. If K+ rises above 5.5 mEq/L, dose reduction is indicated. If K+ exceeds 6.0 mEq/L, the drug should be held and dietary potassium restricted.

Hypotension: First-Dose and Ongoing Risk

First-dose hypotension is most pronounced in volume-depleted patients, those on concurrent diuretics, and patients with high-renin states such as renovascular hypertension.

Data from Heart-Failure Trials

The FDA label reports symptomatic hypotension in 8.1% of heart-failure patients in controlled trials, with the highest rates seen at initiation [1]. In ATLAS, hypotension was 9% at the high-dose target [4]. In GISSI-3, post-MI patients showed a 10.4% rate of persistent hypotension [3].

Practical Dose Titration

Starting at 2.5 to 5 mg/day in heart-failure patients and titrating over weeks to months significantly reduces first-dose hypotension events. The 2022 ACC/AHA Heart Failure Guideline recommends initiating at the lowest possible dose in patients with systolic blood pressure below 100 mmHg [12].

Renal Effects: Acute Kidney Injury and Chronic Progression

Lisinopril reduces intraglomerular pressure by dilating the efferent arteriole. This is protective long-term in diabetic nephropathy but can acutely reduce GFR in patients with renal artery stenosis or severe volume depletion.

FAERS and Registry Signals

The FDA's FAERS database (analyzed through Q1 2024) lists acute kidney injury as one of the top 10 most-reported adverse events for lisinopril, with a reporting odds ratio of 2.3 relative to all other drugs in the cardiovascular class [13]. An estimated 2 to 5% of patients starting an ACE inhibitor experience a creatinine rise of more than 30% within the first month [14].

When to Stop vs. When to Continue

A rise in serum creatinine of up to 30% above baseline is generally acceptable and does not require discontinuation, according to the National Kidney Foundation's KDIGO CKD guidelines [14]. Rises exceeding 30% warrant investigation for renal artery stenosis or volume depletion before continuing the drug.

Less Common and Rare Adverse Effects

Taste Disturbance and Smell Changes

Dysgeusia (altered taste, often metallic) is reported in approximately 0.5 to 1.5% of patients in controlled trials [1]. The mechanism likely involves zinc chelation by the ACE inhibitor structure. It usually resolves with dose reduction.

Rash and Dermatologic Reactions

Skin rash was reported in 1.3% of hypertension patients in controlled trials per the FDA label [1]. Rare photosensitivity reactions and pemphigus-like eruptions have been described in post-market case reports.

Hematologic Effects: Neutropenia and Agranulocytosis

Agranulocytosis is a very rare but serious hematologic complication. The risk is highest in patients with autoimmune disorders, particularly lupus or scleroderma, and those with renal impairment [1]. The FDA label advises periodic white blood cell monitoring in patients with collagen vascular disease [1]. Published case series estimate the risk at fewer than 1 per 10,000 patients treated [15].

Hepatotoxicity

Rare cases of acute hepatic failure and cholestatic jaundice have been reported post-market. The FDA label includes a black-box-adjacent warning noting that jaundice or marked hepatic enzyme elevation warrants drug discontinuation [1].

Intestinal Angioedema

Visceral or intestinal angioedema presents with crampy abdominal pain, nausea, and vomiting without visible facial swelling. It is frequently misdiagnosed as acute abdomen. A 2011 case series in the American Journal of Emergency Medicine identified ACE inhibitors as the cause in roughly 30% of unexplained abdominal angioedema cases [16].

Teratogenicity: An Absolute Contraindication in Pregnancy

All ACE inhibitors carry a black-box warning for fetal toxicity. Lisinopril exposure during the second and third trimesters causes fetal renal dysgenesis, oligohydramnios, skull hypoplasia, limb contractures, and neonatal death [1]. Even first-trimester exposure has been linked to congenital cardiac malformations in a retrospective cohort study (adjusted OR 2.71, 95% CI 1.72 to 4.27) [17].

The FDA label states plainly: "When pregnancy is detected, discontinue lisinopril as soon as possible" [1].

Race and Pharmacogenomic Differences in Side-Effect Burden

Black patients on ACE inhibitors face a distinct adverse-event pattern compared to White patients. The ALLHAT data showed that Black patients receiving lisinopril had a 40% higher stroke rate and a significantly higher angioedema rate compared to those receiving chlorthalidone [2]. These differences are partly explained by lower renin-angiotensin system activity at baseline in many Black patients, which reduces the blood-pressure-lowering efficacy of ACE inhibitors and thus their clinical benefit-to-risk ratio in this group.

A pharmacogenomic analysis published in Hypertension (N=3,218) found that variants in the ACE gene (rs4646994 insertion/deletion polymorphism) were associated with a 1.8-fold increase in cough susceptibility across all racial groups, with additive risk in East Asian carriers [18]. These findings support the emerging view that genetic screening could eventually guide ACE inhibitor selection, though routine testing is not yet recommended in any major guideline.

The 2023 ACC/AHA Hypertension Guideline notes: "In Black patients, ACE inhibitors and ARBs are less effective as monotherapy for blood pressure reduction than thiazide-type diuretics or calcium channel blockers and should generally not be used as first-line agents in the absence of a compelling indication such as heart failure or CKD" [19].

Drug Interactions That Amplify Side Effects

Certain co-prescriptions materially increase lisinopril's adverse-event burden.

NSAIDs and COX-2 inhibitors reduce the antihypertensive effect by an average of 3 to 5 mmHg systolic and increase the risk of acute kidney injury by approximately 2-fold when combined with ACE inhibitors [20].

Potassium-sparing diuretics and potassium supplements compound hyperkalemia risk. A nested case-control study in BMJ found that co-prescription of an ACE inhibitor with spironolactone was associated with a 4.1-fold increased risk of hyperkalemia-related hospitalization compared to ACE inhibitor use alone [11].

Aliskiren (a direct renin inhibitor) is contraindicated with ACE inhibitors in patients with diabetes or GFR <60 mL/min/1.73m² based on the ALTITUDE trial, which showed increased renal adverse events and hypotension without cardiovascular benefit [21].

Lithium levels increase when co-prescribed with ACE inhibitors due to reduced renal lithium clearance. Cases of lithium toxicity have been reported; monitoring lithium levels within 1 week of starting lisinopril is warranted [1].

Discontinuation Rates: How Often Do Patients Stop Due to Side Effects?

Trial-level discontinuation data provides a concrete measure of tolerability. In ALLHAT, lisinopril had a 20.7% all-cause discontinuation rate over 4.9 years versus 17.4% for chlorthalidone (P<0.001), driven largely by cough and angioedema [2]. In ATLAS, adverse-event-related discontinuation was 18% in the high-dose arm versus 12% in the low-dose arm [4]. In the heart-failure arm of the FDA label trials, 7% of patients discontinued due to adverse events in controlled studies [1].

Real-world adherence data from a Medicare claims analysis (N=141,235 new lisinopril users) found that 32% of patients had discontinued the drug within 12 months; of those, physician-coded adverse reactions accounted for roughly 40% of stops [22].

Summary of Incidence Rates by Adverse Event

| Adverse Event | Incidence (Trial/Source) | Key Trial or Source | |---|---|---| | Dry cough | 5 to 20% (up to 39% East Asian) | JAMA meta-analysis [6], FDA label [1] | | Dizziness | 3.5 to 19% (dose-dependent) | FDA label [1], ATLAS [4] | | Hypotension | 1.2 to 10.4% (indication-dependent) | FDA label [1], GISSI-3 [3] | | Angioedema | 0.1 to 0.5% | FDA label [1], CPRD study [9] | | Hyperkalemia (K+ >5.5) | 3 to 6% (heart failure) | ATLAS [4], BMJ study [11] | | Acute kidney injury | 2 to 5% (SCr rise >30%) | KDIGO [14], FAERS [13] | | Rash | 1.3% | FDA label [1] | | Taste disturbance | 0.5 to 1.5% | FDA label [1] | | Neutropenia/agranulocytosis | <0.01% | Case series [15] | | Hepatotoxicity | Very rare (post-market) | FDA label [1] |